Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW). Arzerra (ofatumumab) is submitted for the approval ...
Tags: new drug application, Arzerra, chronic lymphocytic leukemia
Genmab has announced that GlaxoSmithKline (GSK) entered into a patent settlement agreement with Genentech and City of Hope for Ofatumumab. GSK is Genmab's development and commercial collaborator for the CD20 antibody of atumumab. ...